RecruitingPhase 1NCT05528341

NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors

Clinical Investigation of NKG2D-CAR-NK92 Chimeric Antigen Receptor Modified NK92 Cells in the Treatment of Relapsed/Refractory Solid Tumors

Sponsor

Henan Medical University

Enrollment

20 participants

Start Date

Jan 26, 2023

Study Type

INTERVENTIONAL

Conditions

Relapsed/Refractory Solid Tumors

Summary

The purpose of this clinical investigation is to evaluate the safety and effects of NKG2D-CAR-NK92 infusions in the treatment of relapsed/refractory solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called NKG2D-CAR-NK92 cells for people with relapsed/refractory solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALNKG2D-CAR-NK92 cells

NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10\^6-2×10\^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.

Locations(1)

The first Affiliated Hospital of Xinxiang Medical University

Xinxiang, Henan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05528341